Heart failure & cardiomyopathies
Impact of Tafamidis on Myocardial Function and Cardiac Magnetic Resonance (CMR) Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy
Authors' conclusion
Compared with untreated ATTR-CM patients, initiation of tafamidis preserved CMR-measured biventricular function and reduced LV mass at 12 months. ECV and native T1-mapping did not change significantly comparable to baseline in both groups.
Study context
- Population
- Patients with ATTR-CM; mean age 78.3 ± 6.5 (tafamidis) and 76.9 ± 6.5 (untreated)
- Participants
- 36 vs 15
- Exposure
- Tafamidis vs untreated
- Tafamidisn = 36
- Untreatedn = 15reference
- Outcome
- Longitudinal changes in cardiac structure and function by CMR (biventricular function, global longitudinal strain (GLS), LV mass, ECV)
- Follow-up
- 12 months
Methodological detailsuntreated historic control cohort
- Untreated historic control cohort
Main finding
As reported in the abstract
12-month change in CMR biventricular function, LV-GLS and LV mass
| Group | LVEF (%), mean ± SD, baseline to 12 months | RVEF (%), mean ± SD, baseline to 12 months | LV-GLS, mean ± SD, baseline to 12 months | LV mass, mean ± SD, baseline to 12 months |
|---|---|---|---|---|
| Tafamidis | 50.5 ± 12 to 50.7 ± 11.5, P = 0.87 | 48.2 ± 10.4 to 48.2 ± 9.4, P = 0.99 | −9.6 ± 3.2 to −9.9 ± 2.4%; P = 0.595 | 184.7 ± 47.7 to 176.5 ± 44.3 g; P = 0.011 |
Tafamidis
LVEF (%), mean ± SD, baseline to 12 months50.5 ± 12 to 50.7 ± 11.5, P = 0.87
RVEF (%), mean ± SD, baseline to 12 months48.2 ± 10.4 to 48.2 ± 9.4, P = 0.99
LV-GLS, mean ± SD, baseline to 12 months−9.6 ± 3.2 to −9.9 ± 2.4%; P = 0.595
LV mass, mean ± SD, baseline to 12 months184.7 ± 47.7 to 176.5 ± 44.3 g; P = 0.011
- Tafamidis vs Untreated: P (change over time between groups) = 0.032 — RV function
- Tafamidis vs Untreated: P (change over time between groups) = 0.048 — LV-GLS
- Tafamidis vs Untreated: P (change over time between groups) = 0.027 — LV mass
- Irrespective of tafamidis, ECV and native T1-mapping did not change significantly from baseline to 12 months
- P > 0.05
Observational data: associations, not effects.
Further findings
ECV and native T1-mapping · 12 months
- No significant change from baseline in either group
- P > 0.05
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy. ESC Heart Fail. Published 12 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →